Anxiety-Focused Stock Vistagen Therapeutics Is An Undervalued Late-Stage Neurology Player: Analyst
Portfolio Pulse from Vandana Singh
Stifel initiated coverage on Vistagen Therapeutics Inc (VTGN) with a Buy rating and a $12 price target, citing the potential of its lead asset, fasedienol, for social anxiety disorder. Despite a mixed outcome in previous studies, success in upcoming trials could support a marketing application. VTGN's valuation is seen as undervalued for a phase 3 CNS asset, with a current market cap around $60 million. VTGN shares rose 16.90% to $3.19.
November 14, 2023 | 7:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Stifel initiated coverage on VTGN with a Buy rating and a $12 price target, highlighting the potential of fasedienol for treating social anxiety disorder. The company's valuation is considered undervalued, and shares have recently risen by 16.90%.
The initiation of coverage by Stifel with a Buy rating and a significant price target suggests strong analyst confidence in VTGN's lead asset, fasedienol. The positive sentiment is likely to influence investor perception positively in the short term, especially with the recent share price increase. The market cap valuation being described as undervalued for a phase 3 CNS asset further supports the potential for upside.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100